However, in a phase III study, T-VEC plus anti-PD-1 did not significantly improve progression-free survival or OS compared with placebo plus anti-PD-1 in patients with advanced melanoma.65 This suggests that it is important to design OVs based on the TME. The gene discussed is PDCD1; the disease is melanoma.